Last month, Netflix released the trailer for a docuseries called “How to Change Your Mind,” which was adapted from Michael Pollan’s book on the science of psychedelics and what it could teach us about depression, addiction, dying, consciousness and transcendence. Based on Pollan’s experiences and experiments with psychedelics, the docuseries was broken down into four 50-minute episodes with each focusing on a different psychedelic drug. The first episode discusses LSD while subsequent episodes cover psilocybin, MDMA and mescaline respectively.
For plenty of people, Netflix’s new docuseries is the first time they are exposed to the growing world of psychedelic-assisted treatments. More specifically, there has been increased research into using psychedelics to address mental health issues and the series delivers on this front beautifully. During the series, more than a dozen people talk about their experiences with psychedelics, describing the struggles that nearly brought them to rock bottom and how they were able to turn things around thanks to guided psychedelic experiences.
In the second episode, which covers psilocybin, the main hallucinogenic component in magic mushrooms, a man called Ben talks about how crippling obsessive-compulsive disorder (OCD) left him suffering from regular anxiety episodes that evolved into panic attacks when he had a child. After signing up for a psilocybin-assisted therapy clinical trial, Ben describes a profound psilocybin experience that showed him how his life could be if he stopped letting OCD run his life. While under the influence of psilocybin, Ben relieved a traumatic incident from his childhood that resulted in the death of his friend.
He then saw himself dying, turning into dirt and growing into a tree. He was able to see his human self playing with his firstborn while in his tree form, an experience he refers to as beautiful. The hallucination continued, making him relive his entire life and showing him just how different things could have been if he took control of his life away from his OCD.
Months after his psychedelic experience, Ben tells Pollan that he has had zero OCD symptoms.
Stories like Ben’s are told across the series, with people giving firsthand accounts, sometimes in excruciatingly painful detail, of how they were able to change the trajectory of their lives through psychedelic-assisted treatments. These accounts are accompanied by beautifully animated art to that illustrates the psychedelic experience to the audience.
As a whole, “How to Change Your Mind” is an entertaining and informative docuseries that shows the medical potential of psychedelic-assisted therapies and shows real-world examples of people who benefited from such treatments.
The docuseries aside, a number of companies, such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), are advancing product-development programs aimed at bringing novel psychedelic medicines into the mainstream medical field so that mental health ailments can be treated more effectively.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
